Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 24 April 2018

Indication(s)

Xeloda is indicated for the treatment of:
-for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer.
- metastatic colorectal cancer.
- first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.
- in combination with docetaxel for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.
- as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Communicating Metastatic Breast Cancer Learning Zone

Communicating Metastatic Breast Cancer Learning Zone

This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Breakthrough Cancer Pain Learning Zone

Breakthrough Cancer Pain Learning Zone

Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000316
Orphan designation No
Date First Approved 02-02-2001
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Roche Registration Ltd.